ARS Pharmaceuticals

• United States

Sources: sec.gov

• An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

  Phase 2, Recruiting, 42 people, Apr 15, 2025

• Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

  Phase 4, Recruiting, 600 people, Feb 19, 2025

• Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

  Phase 1, Completed, 15 people, Jun 18, 2021

Sources: clinicaltrials.gov

• Series B

  $23.9M, Sep 1, 2020

• Series B

  $23M, Jul 1, 2020

• Series B

  $21.5M, Mar 1, 2020

• Series A

  $7.5M, Dec 1, 2018

• Series A

  $12.5M, Sep 1, 2018

• Series A

  $25M, May 1, 2017

• Series A

  $10M, Apr 1, 2016

Sources: sec.gov